Payload Information
General Information of This Payload
| Payload ID | PAY0FGSQY |
|||||
|---|---|---|---|---|---|---|
| Name |
TAMTM
|
|||||
| Synonyms |
TAMTM
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
BIO-106 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have advanced/metastatic solid tumors with disease progression post-standard therapy, measurable disease (RECIST 1.1 or bone-only), and ECOG 0-1. Exclusions cover drug hypersensitivity, cardiac dysfunction, active infections (HIV/HBV/HCV/SARS-CoV-2), and untreated CNS metastases.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Phase Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)
|
||||
| Primary Endpoint |
The Phase 1 escalation period assesses safety (AEs, SAEs, DLTs) over 1 year to determine MTD, while the Phase 2 expansion period evaluates anti-tumor activity through ORR, DCR, DOR, PFS, and OS over 2 years.
|
||||
| Other Endpoint |
Phase 1 measures anti-tumor activity (ORR, DCR, DOR, PFS, OS) over 1 year, while Phase 2 monitors AESIs and AEs/SAEs over 2 years. PK parameters (Cmax, AUC) and anti-drug antibodies for BIO-106 are tracked across both phases.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320588 | Phase Status | Phase 1/2 | ||
| Clinical Description |
A phase 1/2 study of BIO-106 as monotherapy or in combination with pembrolizumab in patients with advanced cancers (starbridge-1).
|
||||
References